本求人は候補者が決定したため募集を打ち切りました。This advertisement was withdrawn because the position has been filled.

The University of Texas MD Anderson Cancer Center, Department of Leukemia, Section of Molecular Hematology and Therapy、Dr Michael Andfeeffの研究室では、テクニカルスタッフを募集いたします。p53経路を主なターゲットとした白血病分子治療の前臨床研究、および早期臨床研究のバイオマーカーの探索に携わっていただきます。具体的な実験の内容は、動物実験、細胞培養、ウェスタンブロッティング、フローサイトメトリー、PCRなどです。協調性のある、意欲あふれる方を歓迎します。

[募集人数]　１名
[応募資格]　生物・医学分野にて大学卒業後研究経験のある方
[赴任時期]　随時

ご興味を持った方は履歴書（学歴と研究歴・業績、英文）を以下にe―mailしてください。

小島　研介
Kensuke Kojima, M.D., Ph.D.
Visiting Associate Professor
E-mail: kkojima(*)mdanderson.org 「(*)を@と読み替えてください」

参考文献：
Kojima K, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150-3159.

Kojima K, et al. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006;108:993-1000.

Kojima K, et al. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle. 2006;5:2778-2786.

Kojima K, et al. MEK inhibition enhances nuclear proapoptotic function of p53 in AML cells. Cancer Res. 2007;67:3210-3219.

Kojima K, et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 2008;22:1728-1736.

Kojima K, et al. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood. 2008;112:2886-2895.

Kojima K, et al. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 2009;100:1128-1136.

Kojima K, et al. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 via Mcl-1/Noxa axis. Leukemia. 2010;24:33-43.

Kojima K, et al. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther. 2010;9:2545-2557.